Vote Scores

Home / Companies / CRISPR THERAPEUTICS AG

Company · votes reported on Form N-PXCRSP · SEC company no. 1674416

CRISPR THERAPEUTICS AG

How funds and institutional managers reported voting their shares, year to 30 June 2026

Filers reporting
630year to 30 June 2026
Against management on pay
45.9%264 of 575 reporting filers
Same, by reported shares
29.1%shares reported on Form N-PX
Meetings on file
3across 3 seasons
46.8% for42.9% against10.3% other45.9% against management622 filers on say-on-pay

foragainstabstain, withhold or otheramber tick: the portion cast against management

For the year to 30 June 2026, 630 funds and managers listed CRISPR THERAPEUTICS AG in their Form N-PX filings (2 meetings).

On the advisory vote on executive pay, 264 of the 575 filers that reported a position voted against management (45.9%), 39.3 percentage points above the median company on this site (6.6%). By reported shares the figure is 29.1% (median 2.9%). These are shares of the filers reporting on Form N-PX, not of all votes cast at the meeting.

Meetings

Meeting dateSeasonFilers reportingItemsAgainst management on pay
4 Jun 2026year to 30 June 2026625745.9%
5 Jun 2025year to 30 June 2025516760.0%
30 May 2024year to 30 June 2024538748.8%

Meetings with 20 or more reporting filers have their own page with every item. Dates are as filers typed them; dates up to three days apart are treated as one meeting.

Say-on-pay: this company and the median

year to 30 June 2026CRISPR THERAPEUTICS AGMedian company
Reporting filers voting against management45.9%6.6%
Reported shares voted against management29.1%2.9%

Among filers reporting on Form N-PX. The median is over 3,799 companies with a say-on-pay item reported by 20 or more filers.

How the largest families voted

Meeting of 4 Jun 2026: say-on-pay and each shareholder proposal that could be told apart.

FamilySay-on-pay
VanguardFor
BlackRock and iSharesFor
FidelityAgainst *
DimensionalAgainst *
State Street and SPDRFor
American CenturyFor
Franklin TempletonAgainst *
InvescoAgainst *
EquitableAgainst *
Charles SchwabAgainst *
Nuveen and TIAAAgainst *
ProShares and ProFundsAgainst *
John Hancock and ManulifeAgainst *
Morgan Stanley, Eaton Vance and CalvertAgainst *
J.P. MorganFor
Goldman SachsAgainst *
WisdomTreeFor
PGIM and PrudentialAgainst *
Jackson National fundsFor
Northern Trust and FlexSharesAgainst *
SEIAgainst *
T. Rowe PriceFor
Lincoln FinancialFor
VoyaFor
First TrustAgainst *
Russell InvestmentsAgainst *
NationwideAgainst *
Brighthouse FundsFor
Guggenheim and RydexAgainst *
Columbia ThreadneedleAgainst *
BNY MellonFor
PrincipalSplit or no vote
Capital Group and American FundsAgainst *
Pacific Life fundsFor
Global XAgainst *
Federated HermesAgainst *
AllianceBernsteinAgainst *
DWSAgainst *
PIMCOAgainst *
AllspringAgainst *
MassMutualFor
Neuberger BermanAgainst *
American BeaconFor
Natixis and Loomis SaylesAgainst *
Lord AbbettFor
BairdAgainst *

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

By season

SeasonFilers reportingAgainst management on pay, filersBy reported sharesSay-on-pay split
year to 30 June 202454248.8%withheld
year to 30 June 202552760.0%23.1%
year to 30 June 202663045.9%29.1%

Category mix

Share of the vote records reported for this company, by the category filers chose.

CategoryVote recordsShare
DIRECTOR ELECTIONS7,21038.2%
COMPENSATION3,92020.8%
SECTION 14A SAY-ON-PAY VOTES2,98515.8%
CORPORATE GOVERNANCE2,77014.7%
CAPITAL STRUCTURE1,1576.1%
AUDIT-RELATED5442.9%
OTHER2661.4%

Questions

How did large funds vote at CRISPR THERAPEUTICS AG?

For the year to 30 June 2026, 575 Form N-PX filers reported a say-on-pay vote at CRISPR THERAPEUTICS AG; 264 voted against management (45.9%). The table on this page lists the position of each of the largest fund families on say-on-pay and on each shareholder proposal that could be told apart in the filings.

Were there shareholder proposals at CRISPR THERAPEUTICS AG?

No proposal from security holders was reported by enough filers to be shown for the year to 30 June 2026.

Is this the meeting result?

No. The figures are shares of the funds and managers that file Form N-PX, and of the shares they reported. Holders that do not file the form (individuals, most foreign investors, insiders) are not included, so the split here can differ widely from the certified result, which CRISPR THERAPEUTICS AG reports on Form 8-K.

Where does the data come from?

From Form N-PX filings on the SEC's EDGAR system, grouped by company. Filers type company names and meeting dates themselves; this site groups spellings of the same company and folds meeting dates up to three days apart. Data runs through 23 Sep 2026; the median compares 3,799 companies.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list CRISPR THERAPEUTICS AG, grouped by company. The name is the most common spelling among filers; the ticker and SEC company number come from the SEC company tickers file, matched on the exact name. Not verified by the SEC. Filings read through 23 Sep 2026; page built 26 Sep 2026.